Buflomedil HClCAS# 35543-24-9 |
- Risedronate Sodium
Catalog No.:BCC2501
CAS No.:115436-72-1
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- Methylcobalamin
Catalog No.:BCC5188
CAS No.:13422-55-4
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Sulfasalazine
Catalog No.:BCC2545
CAS No.:599-79-1
- SC 144
Catalog No.:BCC1171
CAS No.:895158-95-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 35543-24-9 | SDF | Download SDF |
| PubChem ID | 6420013 | Appearance | Powder |
| Formula | C17H26ClNO4 | M.Wt | 343.85 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 55 mg/mL (159.95 mM) DMSO : 33.33 mg/mL (96.93 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one;hydrochloride | ||
| SMILES | [Cl-].COc1cc(OC)c(C(=O)CCC[NH+]2CCCC2)c(OC)c1 | ||
| Standard InChIKey | ZDPACSAHMZADFZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H25NO4.ClH/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18;/h11-12H,4-10H2,1-3H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Buflomedil HCl Dilution Calculator
Buflomedil HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9082 mL | 14.5412 mL | 29.0824 mL | 58.1649 mL | 72.7061 mL |
| 5 mM | 0.5816 mL | 2.9082 mL | 5.8165 mL | 11.633 mL | 14.5412 mL |
| 10 mM | 0.2908 mL | 1.4541 mL | 2.9082 mL | 5.8165 mL | 7.2706 mL |
| 50 mM | 0.0582 mL | 0.2908 mL | 0.5816 mL | 1.1633 mL | 1.4541 mL |
| 100 mM | 0.0291 mL | 0.1454 mL | 0.2908 mL | 0.5816 mL | 0.7271 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease.
- YM-155 hydrochloride
Catalog No.:BCC2066
CAS No.:355406-09-6
- 6'-O-p-Hydroxybenzoylcatalposide
Catalog No.:BCN5297
CAS No.:355143-38-3
- Ki16425
Catalog No.:BCC1155
CAS No.:355025-24-0
- Ki16198
Catalog No.:BCC4560
CAS No.:355025-13-7
- TCS 1205
Catalog No.:BCC7819
CAS No.:355022-97-8
- 3-beta-O-(trans-p-Coumaroyl)maslinic acid
Catalog No.:BCN1452
CAS No.:35482-91-8
- Balicatib
Catalog No.:BCC5139
CAS No.:354813-19-7
- SC-514
Catalog No.:BCC4554
CAS No.:354812-17-2
- Corianin
Catalog No.:BCN5296
CAS No.:35481-77-7
- Hirsuteine
Catalog No.:BCN2756
CAS No.:35467-43-7
- Caraphenol A
Catalog No.:BCN5295
CAS No.:354553-35-8
- INO-1001
Catalog No.:BCC2212
CAS No.:3544-24-9
- N,N-dimethyl-2-Quinoxalinamine
Catalog No.:BCC9066
CAS No.:35552-76-2
- tert-Butyl rosuvastatin
Catalog No.:BCC9163
CAS No.:355806-00-7
- Betmidin
Catalog No.:BCN8253
CAS No.:35589-22-1
- Fluocinonide
Catalog No.:BCC4953
CAS No.:356-12-7
- Darapladib
Catalog No.:BCC1515
CAS No.:356057-34-6
- Toceranib
Catalog No.:BCC2005
CAS No.:356068-94-5
- N-Desethyl Sunitinib
Catalog No.:BCC1792
CAS No.:356068-97-8
- CP 20961
Catalog No.:BCC6063
CAS No.:35607-20-6
- Mesuaxanthone A
Catalog No.:BCN5298
CAS No.:3561-81-7
- Benzbromarone
Catalog No.:BCC4634
CAS No.:3562-84-3
- NSC 3852
Catalog No.:BCC2423
CAS No.:3565-26-2
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
Quantification of the Vasoactive Agent Buflomedil HCl in Pharmaceutical Formulation and Human Serum by Stripping Voltammetry and Liquid Chromatography.[Pubmed:24061728]
Acta Chim Slov. 2010 Jun;57(2):332-40.
Buflomedil HCl, was reduced at the mercury electrode in buffered solutions of various pH values (2-11) via a single 2-electron irreversible step corresponding to reduction of its C=O double bond. Buflomedil HCl has interfacial adsorptive behavior onto the mercury electrode surface and a monolayer surface coverage of 2.37 x 10-10 mol cm-2 was estimated. Each adsorbed Buflomedil HCl molecule was found to occupy an area of 0.69 nm2 onto the HMDE surface. Differential-pulse (DP), liner-sweep (LS) and square-wave (SW) adsorptive cathodic stripping voltammetry (AdCSV) methods were described for its determination in the bulk form. The sensitivity of the described electro-analytical methods increases in the direction: DP-AdCSV < LS-AdCSV < SW-AdCSV since their achieved limits of detection were: 2.4 x 10-8, 1.5 x 10-8 and 1.2 x 10-9 M bulk Buflomedil HCl, respectively. Besides, a simple high-performance liquid chromatographic method was also developed for determination of bulk Buflomedil HCl with a detection limit of 3.0 x 10-8 M. The described voltammetric and chromatographic methods were successfully applied for determination of Buflomedil HCl in its formulations. Besides these methods were applied for determination of Buflomedil HCl in spiked human serum (limit of detection varying from 1.5 x 10-9 to 4.5 x 10-8 M Buflomedil HCl) without the necessity for pretreatment and/or time-consuming extraction steps prior to the analysis. No significant interferences from excipients or from endogenous human serum substances were obtained. The described SW-AdCS voltammetry method is much more sensitive than the described chromatographic one. However the described chromatographic method is substantially simpler, faster and more sensitive than the previously reported HPLC methods.
Suicide by buflomedil HCl: a case report.[Pubmed:15261008]
J Clin Forensic Med. 2004 Feb;11(1):15-6.
A man was found dead in his bed by his relatives; a half-empty wrapping of Loftyl Plus (the trade name of a vasodilator medications containing Buflomedil HCl marketed in Italy) was on the bedside table. GC/MS analysis of a blood sample collected during the autopsy revealed a Buflomedil HCl concentration approximately of about 20 times the therapeutic values.
An experimental overview of a new vasoactive drug: buflomedil HCl.[Pubmed:7034590]
Angiology. 1981 Oct;32(10):663-75.
A brief review of the pharmacology, pharmacokinetics, and metabolism of buflomedil-HCl is presented providing a pharmacologic basis for buflomedil therapy of ischemia associated with peripheral vascular disease. Buflomedil is readily absorbed in the gastrointestinal tract and has a plasma half-life of approximately 2-3 hours. The para-desmethyl derivative of buflomedil has been identified as a urinary metabolite. Pharmacologically, buflomedil increases perfusion to impaired vascular beds of the microcirculation, increases arterial perfusion with minimal effects on central hemodynamics, exhibits apparent oxygen "sparing" effects in animal experiments, demonstrates inhibitory effects on platelet aggregation, and, in preliminary experiments, appears to improve deformability of erythrocytes with abnormal fluidity. A nonspecific alpha-receptor blocking activity appears to be involved, at least in part, in these pharmacologic effects. The relative importance of these mechanisms/effects in the treatment of symptoms of vascular disease is unknown.
